Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.
about
Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancersAssociation of Protein Translation and Extracellular Matrix Gene Sets with Breast Cancer Metastasis: Findings Uncovered on Analysis of Multiple Publicly Available Datasets Using Individual Patient Data ApproachHER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Genome-based risk prediction for early stage breast cancer.Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy.Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche.Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERα- breast cancer.Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells.Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic miceBasal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).A Tumor initiating cell-enriched prognostic signature for HER2+:ERα- breast cancer; rationale, new features, controversies and future directionsRB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.Clinical applications of mouse models for breast cancer engaging HER2/neu.Personalized chemotherapy selection for breast cancer using gene expression profilesTherapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer.Stromal PTEN inhibits the expansion of mammary epithelial stem cells through Jagged-1Mesenchymal stem cells: A new diagnostic tool?Targeting HER2(+) breast cancer: the TBK1/IKKε axisHeterogeneity in ERK activity as visualized by in vivo FRET imaging of mammary tumor cells developed in MMTV-Neu mice.Common and distinct features of mammary tumors driven by Pten-deletion or activating Pik3ca mutation.Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.Targeting Stemness: Implications for Precision Medicine in Breast Cancer.Cancer Stem Cells.KIAA0100 Modulates Cancer Cell Aggression Behavior of MDA-MB-231 through Microtubule and Heat Shock Proteins.Cancer stem cells and HER2 positive breast cancer: The story so far
P2860
Q26822406-B8DF4563-BDF7-4675-B197-424ACE97874BQ30000323-B99F2A75-D488-46F0-AD96-A71DA5F7A178Q33737278-0D93AE34-7E31-49DC-BBE3-5A330DD45D6CQ34359289-27BF6E5A-CBFE-41A1-A419-AB9BB2EB1225Q35562526-78C20CE9-03B0-4040-946C-FF0746EFDFC1Q36165598-D7FF181F-8E00-49A4-8C19-C55E821D14B5Q36410466-781873DF-583F-4F22-9C9C-8F68805A50C2Q36426509-127D03C6-163D-4B38-B810-F02793D402EEQ36476219-88C8993F-E25A-404A-8197-632CB4ABFD98Q36516589-FAE7D181-F05B-4C5B-8FB2-8D33BBDB5809Q36545638-C65696C8-B68C-4BCE-9D83-107D7A5868D2Q36618624-8403C050-3E6C-4CE3-A229-78C84D9809FCQ37207675-128C21D3-2FCF-40B5-88F7-857B756F5598Q37395680-9B3C678C-1540-47A4-9965-3ADF7FFAA19FQ37555940-B383557E-E3A3-4325-95BC-039ABC84A3BFQ37607675-2EDAAA6E-EEBF-4BFF-8DE8-ADCC85717BABQ37679039-BC13A3DE-4404-4807-9EE6-96C2EDFED869Q38214802-8064BDD9-0094-49BA-84C1-30D2432DF3A8Q38875316-5657D0E9-4CA5-42DF-B104-4A048FA5F2C7Q40981186-B8688AFB-1A41-49C3-8C73-E2B74790BC46Q41252362-46CE4B51-7DB9-484A-B770-5866747AD8E3Q41767315-BEA669AA-A6BA-4ABF-B016-3DA5173A53ADQ41851757-D0624CE3-FFA7-48D3-94B8-2DA0B139C012Q41956750-CCBDC21C-7CEE-490E-BA3B-062CAC547BAAQ42231213-F3EF7D85-F696-4086-B9FE-26428C202566Q42573787-F990A79D-7F92-48D8-B1C3-F361984FC44AQ47304779-112DDB94-DD93-4EED-AA26-9FBDA230D9E2Q49544368-FDCB41AF-F42C-4C7D-AE78-D30575381A8BQ53040917-2729F57E-B87D-43C8-A46C-9B06E17396D6Q55466004-20C11072-FEAE-4F75-9095-AB860D5A404BQ57120564-F66B318F-B37F-4D93-B747-9F7622DF23BD
P2860
Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Seventeen-gene signature from ...... uman HER2+:ERα- breast cancer.
@ast
Seventeen-gene signature from ...... uman HER2+:ERα- breast cancer.
@en
type
label
Seventeen-gene signature from ...... uman HER2+:ERα- breast cancer.
@ast
Seventeen-gene signature from ...... uman HER2+:ERα- breast cancer.
@en
prefLabel
Seventeen-gene signature from ...... uman HER2+:ERα- breast cancer.
@ast
Seventeen-gene signature from ...... uman HER2+:ERα- breast cancer.
@en
P2093
P2860
P356
P1476
Seventeen-gene signature from ...... uman HER2+:ERα- breast cancer.
@en
P2093
Eldad Zacksenhaus
Jeff C Liu
Lajos Pusztai
Sean E Egan
Veronique Voisin
William Fraser Symmans
P2860
P304
P356
10.1073/PNAS.1201105109
P407
P577
2012-03-28T00:00:00Z